Human Papillomavirus Protein E6 (E6)-Pipeline Review, H1 2017

Human Papillomavirus Protein E6 (E6)-Pipeline Review, H1 2017


  • Products Id :- GMDHC0774TDB
  • |
  • Pages: 73
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Human Papillomavirus Protein E6 (E6)-Pipeline Review, H1 2017

Summary

Human Papillomavirus Protein E6 (E6)-The Human Papillomavirus (HPV) E6 protein is one of oncoproteins encoded by the virus. It is a 151 amino-acid peptide. It plays a major role in the induction and maintenance of cellular transformation. It acts mainly as an oncoprotein by stimulating the destruction of many host cell key regulatory proteins. The complex E6/E6P targets several other substrates to degradation via the proteasome including host NFX1-91. The resulting increased expression of hTERT prevents the shortening of telomere length leading to cell immortalization.

Human Papillomavirus Protein E6 (E6) pipeline Target constitutes close to 24 molecules. Out of which approximately 17 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 4, 2, 9 and 1 respectively. Similarly, the universities portfolio in Phase II, Preclinical and Discovery stages comprises 2, 3 and 2 molecules, respectively. Report covers products from therapy areas Oncology, Women's Health and Infectious Disease which include indications Human Papillomavirus (HPV) Associated Cancer, Cervical Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Cervical Intraepithelial Neoplasia (CIN), Head And Neck Cancer, Human Papillomavirus Infections and Lung Cancer.

The latest report Human Papillomavirus Protein E6 (E6)-Pipeline Review, H1 2017, outlays comprehensive information on the Human Papillomavirus Protein E6 (E6) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Human Papillomavirus Protein E6 (E6) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope

The report provides a snapshot of the global therapeutic landscape for Human Papillomavirus Protein E6 (E6)

The report reviews Human Papillomavirus Protein E6 (E6)targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Human Papillomavirus Protein E6 (E6) targeted therapeutics and enlists all their major and minor projects

The report assesses Human Papillomavirus Protein E6 (E6)targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Human Papillomavirus Protein E6 (E6) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Human Papillomavirus Protein E6 (E6)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Human Papillomavirus Protein E6 (E6)development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Human Papillomavirus Protein E6 (E6)-Overview

Human Papillomavirus Protein E6 (E6)-Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Human Papillomavirus Protein E6 (E6)-Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Human Papillomavirus Protein E6 (E6)-Companies Involved in Therapeutics Development

Abion Inc

BioNTech AG

Cancer Research Technology Ltd

Etubics Corp

Genexine Inc

Hookipa Biotech AG

Inovio Pharmaceuticals Inc

MedImmune LLC

Rottapharm Biotech Srl

Selecta Biosciences Inc

Tomegavax Inc

Transgene SA

Human Papillomavirus Protein E6 (E6)-Drug Profiles

ABN-301-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Antibodies to Inhibit E6 for HPV Associated Cancer-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ETBX-041-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy for Human Papilloma Virus Associated Cervical Intraepithelial Neoplasia-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Inhibit E6 and E7 for HPV Associated Cervical Cancer-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GX-188E-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HB-201-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

human papillomavirus [serotype 16] vaccine 1-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

human papillomavirus [serotypes 16] vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

human papillomavirus vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

INO-3106-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MEDI-0457-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Inhibit E6 for Human Papillomavirus (HPV) Associated Cancer-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PVX-01-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SEL-701-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit E6 for Human Papillomavirus Associated Cancer-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Subunit Vaccine for HPV Associated Cervical Cancer-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptide to Inhibit HPV E6 Protein for HPV Associated Cancer-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TA-CIN-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TG-4001-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Tricurin-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target HPV E6 for Cervical Intraepithelial Neoplasia-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VGX-3100-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vvax-001-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Human Papillomavirus Protein E6 (E6)-Dormant Products

Human Papillomavirus Protein E6 (E6)-Discontinued Products

Human Papillomavirus Protein E6 (E6)-Product Development Milestones

Featured News & Press Releases

May 10, 2017: Inovio Provides Update on MedImmune Launch of Combination Trial for HPV-associated Head & Neck Cancer

Apr 24, 2017: Inovio Initiates Phase 2 Efficacy Trial with VGX-3100 For HPV-Related Vulvar Pre-Cancers

Mar 06, 2017: Dr Igor Matushansky Appointed Global Head, Research and Development of Hookipa Biotech

Nov 14, 2016: Inovios Cancer Immunotherapy (INO-3112) Generates T Cell Immune Responses in Tumor Tissue and Peripheral Blood in Patients with HPV-Associated Head and Neck Cancer

Oct 24, 2016: Inovio Announces FDA Request for Additional Information For Phase III Program; Trial Initiation Delayed

Oct 17, 2016: Hookipa Secures EUR 4.16 Million Additional Grant Support from the Austrian Research Promotion Agency (FFG) to Develop Arenavirus Vector-Based Cancer Immunotherapies

Oct 12, 2016: Inovio Expands Executive Team to Advance its DNA Immunotherapy Product Portfolio

Jun 21, 2016: Genexine Presents Interim Clinical Data of GX-188E at EUROGIN 2016

Mar 30, 2016: Inovio Pharmaceuticals HPV Immunotherapy Selected as "Best Therapeutic Vaccine" by World Vaccine Congress

Mar 29, 2016: Inovio Updates INO-3112 HPV Immunotherapy Development Plan

Nov 05, 2015: Inovio's INO-3112 Shows Robust Immune Responses in Patients With Head & Neck Cancer

Sep 17, 2015: Inovio Pharmaceuticals Publishes Successful Phase 2b Trial Results of Its HPV Immunotherapy in The Lancet

Jul 23, 2015: Inovio Pharmaceuticals and European Organization for Research and Treatment of Cancer to Collaborate on Large Phase II Cervical Cancer Trial

Apr 23, 2015: Global clinical development accelerated as cervical intraepithelial neoplasia therapeutic, GX-188E received expanded approval for Phase II from Europe

Apr 09, 2015: Inovio Pharmaceuticals' HPV Immunotherapy Recognized as "Best Therapeutic Vaccine" by World Vaccine Congress

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Figures

Number of Products under Development by Stage of Development, H1 2017

Number of Products under Development by Therapy Areas, H1 2017

Number of Products under Development by Indications, H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Top 10 Molecule Types, H1 2017

Number of Products by Stage and Top 10 Molecule Types, H1 2017

List of Tables

Number of Products under Development by Stage of Development, H1 2017

Number of Products under Development by Therapy Areas, H1 2017

Number of Products under Development by Indication, H1 2017

Number of Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Investigation by Universities/Institutes, H1 2017

Products under Investigation by Universities/Institutes, H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Pipeline by Abion Inc, H1 2017

Pipeline by BioNTech AG, H1 2017

Pipeline by Cancer Research Technology Ltd, H1 2017

Pipeline by Etubics Corp, H1 2017

Pipeline by Genexine Inc, H1 2017

Pipeline by Hookipa Biotech AG, H1 2017

Pipeline by Inovio Pharmaceuticals Inc, H1 2017

Pipeline by MedImmune LLC, H1 2017

Pipeline by Rottapharm Biotech Srl, H1 2017

Pipeline by Selecta Biosciences Inc, H1 2017

Pipeline by Tomegavax Inc, H1 2017

Pipeline by Transgene SA, H1 2017

Dormant Projects, H1 2017

Discontinued Products, H1 2017

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Abion Inc, BioNTech AG, Cancer Research Technology Ltd, Etubics Corp, Genexine Inc, Hookipa Biotech AG, Inovio Pharmaceuticals Inc, MedImmune LLC, Rottapharm Biotech Srl, Selecta Biosciences Inc, Tomegavax Inc, Transgene SA

select a license

Single User License
USD 3500 INR 227150
Site License
USD 7000 INR 454300
Corporate User License
USD 10500 INR 681450

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com